DK2376500T3 - 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaenmaleatsalt - Google Patents

11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaenmaleatsalt Download PDF

Info

Publication number
DK2376500T3
DK2376500T3 DK09793626T DK09793626T DK2376500T3 DK 2376500 T3 DK2376500 T3 DK 2376500T3 DK 09793626 T DK09793626 T DK 09793626T DK 09793626 T DK09793626 T DK 09793626T DK 2376500 T3 DK2376500 T3 DK 2376500T3
Authority
DK
Denmark
Prior art keywords
salt
shows
hci
ray diffraction
batch
Prior art date
Application number
DK09793626T
Other languages
English (en)
Inventor
Cheng Hsia Angeline Lee
Anthony Deodaunia William
Brian Dymock
Original Assignee
Cti Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cti Biopharma Corp filed Critical Cti Biopharma Corp
Application granted granted Critical
Publication of DK2376500T3 publication Critical patent/DK2376500T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (14)

1. Maleatsalt af ll-(2-pyrrolidin-l-yl-ethoxy)-14,19-dioxa-5,7,26-triazatetracyclo[19.3.1.1(2,6).l(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaen.
2. Salt ifølge krav 1, hvor saltet er krystallinsk.
3. Salt ifølge krav 1 eller 2, hvor saltet er l:l-saltet.
4. Salt ifølge et hvilket som helst af kravene 1 til 3 der viser på røntgendiffraktion en top på 2-theta-skalaen ved 17,5°±0,5°.
5. Salt ifølge et hvilket som helst af kravene 1 til 3 der viser på røntgendiffraktion en top på 2-theta-skalaen ved 21,3°±0,5°.
6. Salt ifølge et hvilket som helst af kravene 1 til 4 der viser på røntgendiffraktion mindst to toppe på 2-theta-skalaen valgt fra gruppen bestående af 8,3°±0,5°, 8,8°±0,5°, 16,9°±0,5°, 17,5°±0,5°, 19,0°±0,5°, 21,3°±0,5°, 23,8°±0,5°, 25,3°±0,5°, 25,8°±0,5° og 26,8°±0,5°.
7. Salt ifølge et hvilket som helst af kravene 1 til 5 der viser på røntgendiffraktion mindst 4 toppe på 2-theta-skalaen valgt fra gruppen bestående af 8,3°±0,5°, 8,8°±0,5°, 16,9°±0,5°, 17,5°±0,5°, 19,0°±0,5°, 21,3°±0,5°, 23,8°±0,5°, 25,3°±0,5°, 25,8°±0,5° og 26,8°±0,5°.
8. Salt ifølge et hvilket som helst af kravene 1 til 6 der viser på røntgendiffraktion mindst 6 toppe på 2-theta-skalaen valgt fra gruppen bestående af 8,3°±0,5°, 8,8°±0,5°, 16,9°±0,5°, 17,5°±0,5°, 19,0°±0,5°, 21,3°±0,5°, 23,8°±0,5°, 25,3°±0,5°, 25,8°±0,5° og 26,8°±0,5°.
9. Salt ifølge et hvilket som helst af kravene 1 til 7 der viser på røntgendiffraktion toppe på 2-theta-skalaen ved 8,3°±0,5°, 8,8°±0,5°, 16,9°±0,5°, 17,5°±0,5°, 19,0°±0,5°, 21,3°±0,5°, 23,8°±0,5°, 25,3°±0,5°, 25,8°±0,5° og 26,8°±0,5°.
10. Salt ifølge krav 8 der også viser på røntgendiffraktion mindst 1 top på 2-theta-skalaen ved valgt fra gruppen bestående af 10,6°±0,5°, 13°±0,5°, 14,1°±0,5°, 17,5°±0,5°, 18,3°±0,5°, 20,7°±0,5°, 22,3°±0,5°, 22,7°±0,5°, 23,1°±0,5°, 28,2°±0,5°, 28,5°±0,5°, 29,1°±0,5°, 30,5°±0,5°, 31,3°±0,5°, 35,0°±0,5° og 36,8°±0,5°.
11. Salt ifølge krav 9 der også vises på røntgendiffraktionstoppe på 2-theta-skalaen ved 7,0°±0,5°, 9,2°±0,5°, 11,4°±0,5° og 27,5°±0,5°.
12. Farmaceutisk sammensætning omfattende et salt ifølge et hvilket som helst af kravene 1 til 11.
13. Salt ifølge et hvilket som helst af kravene 1 til 11 til anvendelse i behandling eller forebyggelse af en proliferativ lidelse.
14. Salt til anvendelse ifølge krav 13 hvor den proliferative lidelse er cancer.
DK09793626T 2008-12-11 2009-12-09 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaenmaleatsalt DK2376500T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12167608P 2008-12-11 2008-12-11
PCT/SG2009/000474 WO2010068182A1 (en) 2008-12-11 2009-12-09 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene maleate salt

Publications (1)

Publication Number Publication Date
DK2376500T3 true DK2376500T3 (da) 2015-05-04

Family

ID=42103945

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09793626T DK2376500T3 (da) 2008-12-11 2009-12-09 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaenmaleatsalt

Country Status (10)

Country Link
US (1) US8987243B2 (da)
EP (1) EP2376500B1 (da)
AR (2) AR074725A1 (da)
DK (1) DK2376500T3 (da)
ES (1) ES2536276T3 (da)
HR (1) HRP20150413T8 (da)
PL (1) PL2376500T3 (da)
PT (1) PT2376500E (da)
TW (1) TWI457342B (da)
WO (1) WO2010068182A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
BR122021011788B1 (pt) 2005-11-01 2022-01-25 Impact Biomedicines, Inc Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101576159B1 (ko) * 2005-11-16 2015-12-09 에스*바이오 피티이 리미티드 헤테로알킬이 결합된 피리미딘 유도체
WO2010068181A1 (en) * 2008-12-11 2010-06-17 S*Bio Pte Ltd 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt

Also Published As

Publication number Publication date
PT2376500E (pt) 2015-06-02
WO2010068182A1 (en) 2010-06-17
EP2376500A1 (en) 2011-10-19
AR114134A2 (es) 2020-07-22
HRP20150413T8 (en) 2015-08-14
TW201028425A (en) 2010-08-01
TWI457342B (zh) 2014-10-21
AR074725A1 (es) 2011-02-09
HRP20150413T1 (hr) 2015-07-03
ES2536276T3 (es) 2015-05-22
EP2376500B1 (en) 2015-02-25
US20110263616A1 (en) 2011-10-27
PL2376500T3 (pl) 2015-07-31
US8987243B2 (en) 2015-03-24

Similar Documents

Publication Publication Date Title
WO2014093579A2 (en) Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-methyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl)benzamide and its mono hydrochloride salt
US9624242B2 (en) 11-2(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
DK2376500T3 (da) 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaenmaleatsalt
CA2768210C (en) 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt
CA2993356C (en) Processes for preparing an fgfr inhibitor
WO2014147504A2 (en) Process for preparation of 2-chloro-n-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide solid forms
AU2016210725B2 (en) Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
WO2016004911A1 (en) A cocrystal of ivabradine hydrochloride and (r)-mandelic acid and its pharmaceutical composition
KR20220129495A (ko) 단백질 키나제 억제제로서의 헤테로고리 화합물의 결정형
WO2011039670A1 (en) Novel forms of (2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b] indole)